Company intelligence / Profile preview

Solasta

Glasgow, Scotland, United Kingdom

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Field trials in 2023 and 2024 demonstrated that Solasta Bio’s peptide-based bioinsecticides are as effective as or better than standard synthetic chemical insecticides, with high selectivity for insect pests and no harm to beneficial pollinators or vertebrates[1][2][3].

Therapeutic areas: Other
Modalities: Peptides
Industry: Agriculture & AgTech

Partnerships

FMC Corporation (strategic investment)Corteva (strategic investment and partnership)UPL Corporation (Radicle NPP Challenge partnership)[4]

Beyond the preview

Go deeper on Solasta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solasta.

Explore the full profile